• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aytu Biopharma Inc (NQ: AYTU )

    2.350 -0.050 (-2.08%)
    Streaming Delayed Price Updated: 3:55 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 27,237
    Open 2.392
    Bid (Size) 2.270 (5)
    Ask (Size) 2.380 (3)
    Prev. Close 2.400
    Today's Range 2.350 - 2.414
    52wk Range 2.200 - 3.500
    Shares Outstanding 5,567,490
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -18.69%
    -18.69%
    1 Month
    -1.67%
    -1.67%
    3 Month
    -17.89%
    -17.89%
    6 Month
    -27.02%
    -27.02%
    1 Year
    -20.61%
    -20.61%

    More News

    Read More
    Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
    Via ACCESSWIRE
    Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
    Via ACCESSWIRE
    Sidoti Events, LLC's Virtual August Micro-Cap Conference
    Via ACCESSWIRE
    Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
    Via ACCESSWIRE
    Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
    Via ACCESSWIRE
    Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
    Via ACCESSWIRE
    Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
    Via ACCESSWIRE
    Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
    Via Newsfile
    Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
    Via ACCESSWIRE
    AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024
    Via InvestorPlace
    Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
    Via ACCESSWIRE
    Earnings Scheduled For February 14, 2024
    Via Benzinga
    Earnings Preview: Aytu BioPharma
    Via Benzinga
    Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
    Via ACCESSWIRE
    Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
    Via ACCESSWIRE
    Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
    Via ACCESSWIRE
    Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
    Via ACCESSWIRE
    Aytu BioPharma's Earnings: A Preview
    Via Benzinga
    Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
    Via ACCESSWIRE
    Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.